Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

This repository is under review for potential modification in compliance with Administration directives.

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Primary Target

Ribonucleoside-diphosphate reductase RR1

14

Histamine H1 receptor

316

Dopamine D2 receptor

311

DNA

282

Serotonin 2a (5-HT2a) receptor

237

All Match

Any Match

Exclude Selected

Exclude Selected

Development Status

US Previously Marketed

12

US Approved Rx

2

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Approved

14

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

1991

12

2004

2

All Match

Any Match

Exclude Selected

Exclude Selected

Condition

Cancer-related hypercalcemia

12

Non-Hodgkin's lymphoma

12

Relapsed or refractory lymphoma

12

Relapsed or refractory acute lymphoblastic leukemia

2

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Primary

14

All Match

Any Match

Exclude Selected

Exclude Selected

CNS Activity

CNS Penetrant

14

All Match

Any Match

Exclude Selected

Exclude Selected

Originator

Southern Research

2

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

14

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

CAS

14

FDA UNII

14

PUBCHEM

13

EPA CompTox

12

MERCK INDEX

11

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 1

ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 2

ANTINEOPLASTIC AGENTS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 3

ANTIMETABOLITES

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 4

Purine analogues

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Salts, Hydrates, Esters, etc.

12

Principal Form

2

All Match

Any Match

Exclude Selected

Exclude Selected

Showing 1 - 10 of 14 results

First page disabled
Previous page disabled
1
Next page
Next page

Clofarabine triphosphate

YPJ8ZV99ZP

Export Data
Search for Structure

Status:

US Approved Rx (2019)

First approved in 2004

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Ribonucleoside-diphosphate reductase RR1

Conditions:

Relapsed or refractory acute lymphoblastic leukemia

Clofarabine is a anti-cancer drug which was approved by FDA for the treatment of pediatric patients with relapsed or refractory acute lymphoblastic leukemia. After crossing the cell membrane the drug is rapidly metabolized by deoxycytidine kinase to ...

diphosphate and triphosphate metabolites and these metabolites reversibly inhibit hRNR by binding to alpha subunit. Also the triphosphate is incorporated to DNA where it acts as a chain terminator.

GALLIUM CATION

F7K5MP217W

Export Data
Search for Structure

Status:

US Previously Marketed

First approved in 1991

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Ribonucleoside-diphosphate reductase RR1

Serotransferrin

Ribonucleoside-diphosphate reductase RR1

Interleukin-1 beta

Conditions:

Non-Hodgkin's lymphoma

Relapsed or refractory lymphoma

Cancer-related hypercalcemia

Gallium nitrate (brand name Ganite) is a drug that is used to treat hyper-calcemia, or too much calcium in the blood. Ganite exerts a hypocalcemic effect by inhibiting calcium resorption from bone, possibly by reducing increased bone turnover. It was...

shown, that gallium favorably altered the mineral properties to enhance hydroxyapatite crystallization and reduced mineral solubility. The drug also acted on the cellular components of bone to reduce bone resorption by decreasing acid secretion by osteoclasts. Nevertheless, ganite was withdrawn from sale, although the reasons was not the safety or effectiveness. Gallium nitrate inhibits the growth of various lymphoma cell lines in vitro and exhibits antitumor activity in patients with lymphoma. Gallium binds avidly to the iron transport protein transferrin. Transferrin-gallium complexes preferentially target cells that express transferrin receptors on their surface. Expression of transferrin receptors is particularly high on lymphoma cells. Cellular uptake of the gallium-transferrin complex leads to inhibition of cellular proliferation primarily via disruption of iron transport and homeostasis and blockade of ribonucleotide reductase. In phase II of clinical trials in patients with relapsed or refractory lymphoma, the antitumor activity of gallium nitrate is similar to, or better than, that of other commonly used chemotherapeutic agents.

CLOFARABINE

762RDY0Y2H

Export Data
Search for Structure

Status:

US Approved Rx (2019)

First approved in 2004

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Ribonucleoside-diphosphate reductase RR1

Conditions:

Relapsed or refractory acute lymphoblastic leukemia

Clofarabine is a anti-cancer drug which was approved by FDA for the treatment of pediatric patients with relapsed or refractory acute lymphoblastic leukemia. After crossing the cell membrane the drug is rapidly metabolized by deoxycytidine kinase to ...

diphosphate and triphosphate metabolites and these metabolites reversibly inhibit hRNR by binding to alpha subunit. Also the triphosphate is incorporated to DNA where it acts as a chain terminator.

GALLIUM DICITRATE

6ZNH95J8XB

Export Data
Search for Structure

Status:

US Previously Marketed

First approved in 1991

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Ribonucleoside-diphosphate reductase RR1

Serotransferrin

Ribonucleoside-diphosphate reductase RR1

Interleukin-1 beta

Conditions:

Non-Hodgkin's lymphoma

Relapsed or refractory lymphoma

Cancer-related hypercalcemia

Gallium nitrate (brand name Ganite) is a drug that is used to treat hyper-calcemia, or too much calcium in the blood. Ganite exerts a hypocalcemic effect by inhibiting calcium resorption from bone, possibly by reducing increased bone turnover. It was...

shown, that gallium favorably altered the mineral properties to enhance hydroxyapatite crystallization and reduced mineral solubility. The drug also acted on the cellular components of bone to reduce bone resorption by decreasing acid secretion by osteoclasts. Nevertheless, ganite was withdrawn from sale, although the reasons was not the safety or effectiveness. Gallium nitrate inhibits the growth of various lymphoma cell lines in vitro and exhibits antitumor activity in patients with lymphoma. Gallium binds avidly to the iron transport protein transferrin. Transferrin-gallium complexes preferentially target cells that express transferrin receptors on their surface. Expression of transferrin receptors is particularly high on lymphoma cells. Cellular uptake of the gallium-transferrin complex leads to inhibition of cellular proliferation primarily via disruption of iron transport and homeostasis and blockade of ribonucleotide reductase. In phase II of clinical trials in patients with relapsed or refractory lymphoma, the antitumor activity of gallium nitrate is similar to, or better than, that of other commonly used chemotherapeutic agents.

AMMONIUM HEXAFLUOROGALLATE

4X2AHU48WW

Export Data
Search for Structure

Status:

US Previously Marketed

First approved in 1991

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Ribonucleoside-diphosphate reductase RR1

Serotransferrin

Ribonucleoside-diphosphate reductase RR1

Interleukin-1 beta

Conditions:

Non-Hodgkin's lymphoma

Relapsed or refractory lymphoma

Cancer-related hypercalcemia

Gallium nitrate (brand name Ganite) is a drug that is used to treat hyper-calcemia, or too much calcium in the blood. Ganite exerts a hypocalcemic effect by inhibiting calcium resorption from bone, possibly by reducing increased bone turnover. It was...

shown, that gallium favorably altered the mineral properties to enhance hydroxyapatite crystallization and reduced mineral solubility. The drug also acted on the cellular components of bone to reduce bone resorption by decreasing acid secretion by osteoclasts. Nevertheless, ganite was withdrawn from sale, although the reasons was not the safety or effectiveness. Gallium nitrate inhibits the growth of various lymphoma cell lines in vitro and exhibits antitumor activity in patients with lymphoma. Gallium binds avidly to the iron transport protein transferrin. Transferrin-gallium complexes preferentially target cells that express transferrin receptors on their surface. Expression of transferrin receptors is particularly high on lymphoma cells. Cellular uptake of the gallium-transferrin complex leads to inhibition of cellular proliferation primarily via disruption of iron transport and homeostasis and blockade of ribonucleotide reductase. In phase II of clinical trials in patients with relapsed or refractory lymphoma, the antitumor activity of gallium nitrate is similar to, or better than, that of other commonly used chemotherapeutic agents.

GALLIUM OXIDE

46F059V66A

Export Data
Search for Structure

Status:

US Previously Marketed

First approved in 1991

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Ribonucleoside-diphosphate reductase RR1

Serotransferrin

Ribonucleoside-diphosphate reductase RR1

Interleukin-1 beta

Conditions:

Non-Hodgkin's lymphoma

Relapsed or refractory lymphoma

Cancer-related hypercalcemia

Gallium nitrate (brand name Ganite) is a drug that is used to treat hyper-calcemia, or too much calcium in the blood. Ganite exerts a hypocalcemic effect by inhibiting calcium resorption from bone, possibly by reducing increased bone turnover. It was...

shown, that gallium favorably altered the mineral properties to enhance hydroxyapatite crystallization and reduced mineral solubility. The drug also acted on the cellular components of bone to reduce bone resorption by decreasing acid secretion by osteoclasts. Nevertheless, ganite was withdrawn from sale, although the reasons was not the safety or effectiveness. Gallium nitrate inhibits the growth of various lymphoma cell lines in vitro and exhibits antitumor activity in patients with lymphoma. Gallium binds avidly to the iron transport protein transferrin. Transferrin-gallium complexes preferentially target cells that express transferrin receptors on their surface. Expression of transferrin receptors is particularly high on lymphoma cells. Cellular uptake of the gallium-transferrin complex leads to inhibition of cellular proliferation primarily via disruption of iron transport and homeostasis and blockade of ribonucleotide reductase. In phase II of clinical trials in patients with relapsed or refractory lymphoma, the antitumor activity of gallium nitrate is similar to, or better than, that of other commonly used chemotherapeutic agents.

GALLIUM NITRIDE (GAN)

1R9CC3P9VL

Export Data
Search for Structure

Status:

US Previously Marketed

First approved in 1991

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Ribonucleoside-diphosphate reductase RR1

Serotransferrin

Ribonucleoside-diphosphate reductase RR1

Interleukin-1 beta

Conditions:

Non-Hodgkin's lymphoma

Relapsed or refractory lymphoma

Cancer-related hypercalcemia

Gallium nitrate (brand name Ganite) is a drug that is used to treat hyper-calcemia, or too much calcium in the blood. Ganite exerts a hypocalcemic effect by inhibiting calcium resorption from bone, possibly by reducing increased bone turnover. It was...

shown, that gallium favorably altered the mineral properties to enhance hydroxyapatite crystallization and reduced mineral solubility. The drug also acted on the cellular components of bone to reduce bone resorption by decreasing acid secretion by osteoclasts. Nevertheless, ganite was withdrawn from sale, although the reasons was not the safety or effectiveness. Gallium nitrate inhibits the growth of various lymphoma cell lines in vitro and exhibits antitumor activity in patients with lymphoma. Gallium binds avidly to the iron transport protein transferrin. Transferrin-gallium complexes preferentially target cells that express transferrin receptors on their surface. Expression of transferrin receptors is particularly high on lymphoma cells. Cellular uptake of the gallium-transferrin complex leads to inhibition of cellular proliferation primarily via disruption of iron transport and homeostasis and blockade of ribonucleotide reductase. In phase II of clinical trials in patients with relapsed or refractory lymphoma, the antitumor activity of gallium nitrate is similar to, or better than, that of other commonly used chemotherapeutic agents.

GALLIUM(III) HYDROXIDE

S3PJW60NUM

Export Data
Search for Structure

Status:

US Previously Marketed

First approved in 1991

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Ribonucleoside-diphosphate reductase RR1

Serotransferrin

Ribonucleoside-diphosphate reductase RR1

Interleukin-1 beta

Conditions:

Non-Hodgkin's lymphoma

Relapsed or refractory lymphoma

Cancer-related hypercalcemia

Gallium nitrate (brand name Ganite) is a drug that is used to treat hyper-calcemia, or too much calcium in the blood. Ganite exerts a hypocalcemic effect by inhibiting calcium resorption from bone, possibly by reducing increased bone turnover. It was...

shown, that gallium favorably altered the mineral properties to enhance hydroxyapatite crystallization and reduced mineral solubility. The drug also acted on the cellular components of bone to reduce bone resorption by decreasing acid secretion by osteoclasts. Nevertheless, ganite was withdrawn from sale, although the reasons was not the safety or effectiveness. Gallium nitrate inhibits the growth of various lymphoma cell lines in vitro and exhibits antitumor activity in patients with lymphoma. Gallium binds avidly to the iron transport protein transferrin. Transferrin-gallium complexes preferentially target cells that express transferrin receptors on their surface. Expression of transferrin receptors is particularly high on lymphoma cells. Cellular uptake of the gallium-transferrin complex leads to inhibition of cellular proliferation primarily via disruption of iron transport and homeostasis and blockade of ribonucleotide reductase. In phase II of clinical trials in patients with relapsed or refractory lymphoma, the antitumor activity of gallium nitrate is similar to, or better than, that of other commonly used chemotherapeutic agents.

GALLIUM CITRATE

HT6C49L0ZP

Export Data
Search for Structure

Status:

US Previously Marketed

First approved in 1991

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Ribonucleoside-diphosphate reductase RR1

Serotransferrin

Ribonucleoside-diphosphate reductase RR1

Interleukin-1 beta

Conditions:

Non-Hodgkin's lymphoma

Relapsed or refractory lymphoma

Cancer-related hypercalcemia

Gallium nitrate (brand name Ganite) is a drug that is used to treat hyper-calcemia, or too much calcium in the blood. Ganite exerts a hypocalcemic effect by inhibiting calcium resorption from bone, possibly by reducing increased bone turnover. It was...

shown, that gallium favorably altered the mineral properties to enhance hydroxyapatite crystallization and reduced mineral solubility. The drug also acted on the cellular components of bone to reduce bone resorption by decreasing acid secretion by osteoclasts. Nevertheless, ganite was withdrawn from sale, although the reasons was not the safety or effectiveness. Gallium nitrate inhibits the growth of various lymphoma cell lines in vitro and exhibits antitumor activity in patients with lymphoma. Gallium binds avidly to the iron transport protein transferrin. Transferrin-gallium complexes preferentially target cells that express transferrin receptors on their surface. Expression of transferrin receptors is particularly high on lymphoma cells. Cellular uptake of the gallium-transferrin complex leads to inhibition of cellular proliferation primarily via disruption of iron transport and homeostasis and blockade of ribonucleotide reductase. In phase II of clinical trials in patients with relapsed or refractory lymphoma, the antitumor activity of gallium nitrate is similar to, or better than, that of other commonly used chemotherapeutic agents.

GALLIUM TRIFLUORIDE

3EG50JLZ49

Export Data
Search for Structure

Status:

US Previously Marketed

First approved in 1991

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Ribonucleoside-diphosphate reductase RR1

Serotransferrin

Ribonucleoside-diphosphate reductase RR1

Interleukin-1 beta

Conditions:

Non-Hodgkin's lymphoma

Relapsed or refractory lymphoma

Cancer-related hypercalcemia

Gallium nitrate (brand name Ganite) is a drug that is used to treat hyper-calcemia, or too much calcium in the blood. Ganite exerts a hypocalcemic effect by inhibiting calcium resorption from bone, possibly by reducing increased bone turnover. It was...

shown, that gallium favorably altered the mineral properties to enhance hydroxyapatite crystallization and reduced mineral solubility. The drug also acted on the cellular components of bone to reduce bone resorption by decreasing acid secretion by osteoclasts. Nevertheless, ganite was withdrawn from sale, although the reasons was not the safety or effectiveness. Gallium nitrate inhibits the growth of various lymphoma cell lines in vitro and exhibits antitumor activity in patients with lymphoma. Gallium binds avidly to the iron transport protein transferrin. Transferrin-gallium complexes preferentially target cells that express transferrin receptors on their surface. Expression of transferrin receptors is particularly high on lymphoma cells. Cellular uptake of the gallium-transferrin complex leads to inhibition of cellular proliferation primarily via disruption of iron transport and homeostasis and blockade of ribonucleotide reductase. In phase II of clinical trials in patients with relapsed or refractory lymphoma, the antitumor activity of gallium nitrate is similar to, or better than, that of other commonly used chemotherapeutic agents.

Showing 1 - 10 of 14 results

First page disabled
Previous page disabled
1
Next page
Next page

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1